Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$67.81 USD

67.81
4,294,477

-0.25 (-0.37%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $67.84 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (152 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Syneos Health-Idorsia Collaborate to Launch Daridorexant in US

by Zacks Equity Research

Syneos Health (SYNH) inks deal with Idorsia to commercialize the treatment for insomnia in the United States.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Lab, Quidel, Becton, Dickinson and Company, Hologic and Quest Diagnostics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Lab, Quidel, Becton, Dickinson and Company, Hologic and Quest Diagnostics

Zacks Equity Research

Medtronic's (MDT) Cryoablation Suited for Patients With PAF

by Zacks Equity Research

Medtronic's (MDT) cryoablation therapy's superiority for the treatment of PAF over currently available AAD treatment gets reflected in trial results.

Zacks Equity Research

Medtronic (MDT) Sees Trend Rebound Amid Coronavirus Crisis

by Zacks Equity Research

Medtronic's (MDT) procedure volumes start to recover in multiple markets globally.

Zacks Equity Research

Hologic Updates Breast Biopsy System to Enhance Workflow

by Zacks Equity Research

Hologic (HOLX) introduces features to update Brevera Breast Biopsy System in order to transform patient experience and enhance workflow.

Zacks Equity Research

Why Is Hologic (HOLX) Down 11.7% Since Last Earnings Report?

by Zacks Equity Research

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Urmimala Biswas headshot

Price War in Coronavirus Test Space to Intensify Thanks to Abbott

by Urmimala Biswas

Most rapid antigen tests in the United States require an additional system, which is making the procedures more costly and complex.

Zacks Equity Research

Phibro (PAHC) Q4 Earnings Fall Short of Estimates, Margins Up

by Zacks Equity Research

Phibro's (PAHC) core Animal Health segment was aided by the Osprey Biotechnics acquisition despite a dismal overall performance in Q4 due to pandemic-led business disruptions.

Zacks Equity Research

Hologic's Acessa Health Buyout to Broaden GYN Surgical Line

by Zacks Equity Research

Hologic's (HOLX) newly-acquired product line is set to complement its market-leading MyoSure products for hysteroscopic removal of fibroids.

Zacks Equity Research

Align Technology (ALGN) Strong on Robust Customer Adoption

by Zacks Equity Research

Align Technology (ALGN) treats the one millionth patient from the APAC region, highlighting the Invisalign system's continued adoption.

Zacks Equity Research

Medtronic's (MDT) Q1 Earnings Beat Estimates, Margins Fall

by Zacks Equity Research

Barring Respiratory, Gastrointestinal & Renal, Medtronic (MDT) registers dismal performance in all business segments and geographies in Q1.

Zacks Equity Research

Insulet (PODD) Banks on Omnipod Uptake Amid Coronavirus Woes

by Zacks Equity Research

Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.

Zacks Equity Research

Amedisys & BrightStar Ink Agreement to Expand Personal Care

by Zacks Equity Research

Amedisys (AMED) strengthens Personal Care business reach by entering into an agreement with BrightStar.

Zacks Equity Research

QIAGEN (QGEN) to Launch COVID-19 Antibody Test in the US

by Zacks Equity Research

QIAGEN's (QGEN) latest antibody test complements its array of COVID-19 testing solutions in an economical way to detect immune responses in people who have been exposed to the SARS-CoV-2 virus.

Zacks Equity Research

ASCO Recommends Myriad Genetics' Test to Treat Ovarian Cancer

by Zacks Equity Research

Myriad Genetics' (MYGN) myChoice CDx test gets included in ASCO's latest recommendations for advanced ovarian cancer patients.

Zacks Equity Research

Medtronic's (MDT) Evolut TAVR Label Expansion Gets FDA Nod

by Zacks Equity Research

Medtronic's (MDT) Low Risk Bicuspid Study shows bicuspid patients implanted with Evolut TAVR had low rates (1.3%) of all-cause mortality.

Zacks Equity Research

TeleFlex Banks on Urolift Sales Amid Coronavirus-Led Debacle

by Zacks Equity Research

The acquired business of Teleflex (TFX), NeoTract has been performing impressively lately.

Zacks Equity Research

Fluidigm (FLDM) Looks Good: Stock Adds 8.7% in Session

by Zacks Equity Research

Fluidigm (FLDM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Zacks Equity Research

Here's Why You Should Hold on to NuVasive (NUVA) Stock Now

by Zacks Equity Research

Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.

Zacks Equity Research

Medtronic Initiates Post-Market ELITE Study for SNM Therapy

by Zacks Equity Research

Medtronic's (MDT) ELITE study is expected to reinforce long-term safety, efficacy and patient benefit from the SNM therapy.

Zacks Equity Research

Medtronic Publishes IN.PACT AV Access Trial Study Results

by Zacks Equity Research

Medtronic's (MDT) IN.PACT AV demonstrates significant reductions in hospital visits for AV fistulae maintenance, which is leading to successful and uninterrupted dialysis of ESRD patients.

Zacks Equity Research

Globus Medical Sees Strong Rebound Despite Coronavirus Crisis

by Zacks Equity Research

Globus Medical (GMED) witnesses a significant rebound from mid-April through the remainder of Q2.

Zacks Equity Research

QIAGEN Launches Primer Panel for NGS of Coronavirus Genome

by Zacks Equity Research

QIAGEN (QGEN) expands the NGS portfolio with the launch of the genome analyzing panel to support holistic research of the SARS-CoV-2.

Zacks Equity Research

Omnicell (OMCL) Hurt by Coronavirus-Led Lower Product Booking

by Zacks Equity Research

Omnicell (OMCL) is currently witnessing slowdown in purchasing decisions by hospitals.

Urmimala Biswas headshot

Will Thermo Fisher's (TMO) Failed QIAGEN Deal Cost it a Lot?

by Urmimala Biswas

The COVID-19 tailwinds are significantly stronger than what Thermo Fisher (TMO) had originally expected in March.